Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: First, second, and third-line

Frontiers in Oncology

Volumn 4 JUN, Issue , 2014, Pages

  Al Farsi, Abdulaziz ^a   Ellis, Peter Michael ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Chemotherapy; EGFR inhibitors; Immunotherapy; Molecular abnormalities; Non small cell lung cancer; Novel agents; Squamous cancer

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; B RAF KINASE INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; G PROTEIN COUPLED RECEPTOR; GEMCITABINE; K RAS PROTEIN; MPDL 3280A; NECITUMUMAB; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM AGENT; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; PROTEINASE; SORAFENIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADENOCARCINOMA; CANCER CHEMOTHERAPY; CHROMOSOME TRANSLOCATION; EGFR GENE; GENE; GENE AMPLIFICATION; GENE MUTATION; HEMOPTYSIS; HISTOLOGY; HUMAN; IMMUNOTHERAPY; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; THROMBOEMBOLISM;

EID: 84904703074     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00157     Document Type: Short Survey

References (34)

1. Scagliotti GV, de Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol (2002) 20:4285-91. doi: 10.1200/JCO.2002.02.068
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med (2002) 346:92-8. doi:10.1056/NEJMoa011954
3. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol (2000) 18:2354-62.
4. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol (2000) 18:2095-103.
5. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol (2004) 22:1589-97. doi:10.1200/JCO.2004.08.163
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Huat Tan E, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 353:123-32. doi:10.1056/NEJMoa050753
7. Kelly K, Chansky K, Mack PC, Lara PNJr, Hirsch FR, Franklin WA, et al. Chemotherapy outcomes by histologic subtype of non-small cell lung cancer (NSCLC): analysis of the SWOG database for antimicrotubule-platinum therapy. J Thorac Oncol (2009) 4:B2.7. doi:10.1016/j.cllc.2013.06.010
8. Peterson P, Park K, Fossella F, Gatzemeier U, John W, Scagliotti GV, et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol (2007) 2:2-328. doi:10.1097/01.JTO.0000284677.33344.62
9. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist (2009) 14:253-63. doi:10.1634/theoncologist.2008-0232
10. Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res (2012) 18:1167-76. doi:10.1158/1078-0432.CCR-11-2109
11. Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer (2006) 107:1589-96. doi:10.1002/cncr.22208
12. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol (1988) 6:633-41.
13. Kelly K, Crowley J, Bunn PA Jr, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol (2001) 19:3210-8.
14. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 22:2184-91. doi:10.1200/JCO.2004.11.022
15. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 28:1835-42. doi:10.1200/JCO.2009.26.1321
16. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non- small-cell lung cancer. J Clin Oncol (2008) 26:3543-51. doi:10.1200/JCO.2007.15.0375
17. Ciuleanu T, Brodowicz T, Zielinski C, Hang Kim J, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet (2009) 374:1432-40. doi:10.1016/S0140-6736(09)61497-5
18. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol (2010) 11:521-9. doi:10.1016/S1470-2045(10)70112-1
19. Belani CP, Waterhouse DM, Ghazal H, Ramalingam SS, Bordoni R, Greenberg R, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). ASCO Meet Abs (2010) 28:7506.
20. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer (2006) 52:155-63. doi:10.1016/j.lungcan.2006.01.006
21. Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2012) 30:3516-24. doi:10.1200/JCO.2011.39.9782
22. Hainsworth JD, Fang L, Huang JE, Karlin D, Russell K, Faoro L, et al. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol (2011) 6(109-14): doi:10.1097/JTO.0b013e3181f94ad4
23. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol (2010) 28:911-7. doi:10.1200/JCO.2009.21.9618
24. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet (2009) 373:1525-31. doi:10.1016/S0140-6736(09)60569-9
25. Pujol JL, Pirker R, Lynch TJ, Butts CA, Rosell R, Shepherd FA, et al. Chemotherapy (CT) plus cetuximab as 1st-line treatment for advanced non small cell lung cancer (NSCLC): meta-analysis of individual patients data. Ann Oncol (2010) 21:436. doi:10.1016/j.lungcan.2013.11.006
26. Paz-Ares L, Mezger J, Ciuleanu T, Fischer JR, Von Pawel J, Provencio M, et al. Randomized phase-3 trial (INSPIRE) of necitumumab plus cisplatin-pemetrexed versus cisplatin-pemetrexed alone as first-line therapy in stage IV non-squamous NSCLC. J Thorac Oncol (2013) 8(Suppl 2):O03.2.
27. Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer (2004) 43:183-94. doi:10.1016/j.lungcan.2003.09.001
28. Ellis PM, Blais N, Soulieres D, Ionescu DN, Kashyap M, Liu G, et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol (2011) 6:1379-91. doi:10.1097/JTO.0b013e318220cb8e
29. Kris MG, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Aronson SL, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's lung cancer mutation consortium (LCMC). ASCO Meet Abs (2011) 29:CRA7506.
30. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 489:519-25. doi:10.1038/nature11404
31. Hammerman P, Sivachenko A, Pho N, Cherniak A, Ramos A, Getz G, et al. Genomic characterization and targeted therapeutics in squamous cell lung cancer. J Thorac Oncol (2011) 6(Suppl 2):PRS.1.
32. Brahmer JR, Horn L, Antonia SJ, Spigel DR, Gandhi L, Sequist LV, et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase 1 trial. J Thorac Oncol (2013) 8(Suppl 2):MO18.03.
33. Garon EB, Balmanoukian A, Hamid O, Hui R, Gandhi L, Leighl N, et al. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). J Thorac Oncol (2013) 8(Suppl 2):MO18.02.
34. Horn L, Herbst RS, Spigel D, Gettinger SN, Gordon MS, Hollebecque A, et al. An analysis of the relationship of clinical activity to baseline EGFR status, PDL1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDLl3280A (anti-PDL1). J Thorac Oncol (2013) 8(Suppl 2):MO18.01.